Vabomere (Meropenem/Vaborbactam) Patent Expiration, LOE Window & CMS Spending
Vabomere (Meropenem/Vaborbactam) by Rempex A Wholly Owned Sub Of Melinta Therapeutics: FDA Orange Book core substance LOE 2031-08-29 (last listed 2039-04-06), 0 AB generics, $1.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Rempex A Wholly Owned Sub Of Melinta Therapeutics |
| FDA Application & Pathway | N209776 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-08-29 |
| Last Listed Patent or Exclusivity Date | 2039-04-06 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.5M |
| 2024 Medicare Part D Spend | $1.1M |
| 2024 Medicaid Spend | $342K |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 21.2% 2-yr change) |